anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
As a promising alternative to bone marrow aspiration (BMA), mutational profiling on blood-derived circulating cell-free tumor DNA (cfDNA) is a harmless and simple technique to monitor molecular response and treatment resistance of patients with refractory/relapsed multiple myeloma (R/R MM). We evaluated the sensitivity and specificity of cfDNA compared to BMA CD138 positive myeloma plasma cells (PCs) in a series of 45 R/R MM patients using the 29-gene targeted panel (AmpliSeq) NGS. KRAS, NRAS, FAM46C, DIS3, and TP53 were the most frequently mutated genes. The average sensitivity and specificity of cfDNA detection were 65% and 97%, respectively. The concordance per gene between the two samples was good to excellent according to Cohen's κ coefficients interpretation. An increased number of mutations detected in cfDNA were associated with a decreased overall survival. In conclusion, we demonstrated cfDNA NGS analysis feasibility and accuracy in R/R MM patients who may benefit from early phase clinical trial.
1427677 Delayed release medicaments EDELFETTWERKE WERNER SCHLUTER and GLYCO IBERICA SA 14 March 1974 [6 Dec 1973] 11487/74 Heading A5B Delayed release preparations comprise particles of a medicament coated with a fatty acid triglyceride, and a water-soluble calcium salt. The latter may be incorporated in the coated medicament particles or may also be present, e.g. in a capsule or liquid suspension, in the form of particles likewise coated with the triglyceride. The particles may be produced by suspending the particulate material in a molten triglyceride, subdividing the melt and allowing the liquid particles thus formed to solidify in known manner. Alternatively, the melt may be cast into a thin sheet and mechanically subdivided. The particles obtained may be used as indicated above or as constituents of compressed tablets.
PURPOSE:To obtain fertilizer, medicine, etc., at low cost through effectively utilizing bone black by pulverizing the bone black obtained thorugh baking large size bones of cattle and swine, etc., by a pulverizer without supplying air into the powder. CONSTITUTION:This bone black is obtained by recovering bones of cattle and swine, etc., discharged from the livestock industry and baking the recovered bones in a baking furnace wituout supplying air to scatteringly remove nitrogen compounds. The resultant bone black is then pulverized into a powder by using a pulverizer to obtain a fertilizer appropriately used as a phosphatic or potassic fertilizer. The powdery bone black is also useful as an effective medicine against e.g. colon cancer. Further, an acid is added to the powdery bone black and the resultant mixture is stirred and, thereafter, allowed to stand to separate the mixture into precipitated first activated carbon and a supernatant liquid. Then, the resultant suspension is filtered to obtain the first activated carbon having good purity and, at the same time, the supernatant liquid is added to an alkali solution to neutralize and to precipitate first apatite to obtain the first apatite having good purity. The first activated carbon to be obtained has strong adsorptivity and the first apatite can be utilized as an ingredient for dentifrice or cosmetics.
* Sublingual NTG may be taken as required to abort acute anginal attacks during diltiazem hydrochloride tablet therapy. 
  * Prophylactic Nitrate Therapy. Diltiazem hydrochloride tablets may be safely coadministered with short- and long-acting nitrates, but there have been no controlled studies to evaluate the antianginal effectiveness of this combination. 
  * Beta-blockers. (See WARNINGS and PRECAUTIONS.) 

30 mg – Diltiazem tablets may be swallowed whole, crushed, or chewed. Do not split diltiazem tablets.

60 mg, 90 mg, and 120 mg – Diltiazem tablets may be swallowed whole, crushed, or chewed.
INTRODUCTION: Parastomal hernias are a challenging complication of digestive ostomies. Ileal-conduit parastomal hernias after cystectomy have specific aspects. The aim of this study was to describe the incidence and natural history of ileal-conduit parastomal hernias in order to guide their management, as well as to identify risk factors to prevent them.
PATIENTS AND METHODS: All consecutive patients undergoing cystectomy with a Bricker's ileal conduit in 3 academic centers were retrospectively identified. Data were collected regarding their medical history prior to cystectomy, the operation, the postoperative period, imaging results within 5 years of follow-up, and the onset and timing of clinically or radiologically diagnosed ICPH.
RESULTS: Among 577 patients included in the study, 115 (20.6%) developed an ICPH during the study period. Most patients did not present any symptom and the diagnosis was made at imaging in 74.8% of them. Most hernias were detected between 1 and 2 years after the cystectomy, with a mean time to diagnosis of 12.4 months. At multivariate analysis, overweight and obesity were independent risk factors for developing an ICPH (adjusted hazard ratio [aHR] 1.96; p = 0.046), while a trans-rectus position of the ostomy was a significant protective factor (aHR 0.45; p = 0.011).
CONCLUSIONS: A PH develops in almost 20% of patients after ileal conduit urinary diversion, with a mean time of onset of 12.4 months. It is often a subclinical condition detected at medical imaging. Obesity increases the risk, while passing the ileal-conduit through the rectus muscle can help to prevent it.
The study group was treated with Maitland mobilization and manipulation techniques including postero-anterior Maitland mobilization for C1-C2, Maitland lateral PA glide for C3-C6 and Maitland thrust manipulation for cervico-thoracic junction. Frequency of mobilization was 2 days a week for 4 weeks. While intensity of mobilization was grade 3 and 4 based on the Maitland concept.13 Time of oscillations was 2 or 3 oscillations in a second for 1 to 2 minutes.
Children in a primary school, aged between 9 and 12 years, play the serious game (two sessions, duration of each session 35 minutes, within two weeks). The game equips the children with knowledge about the core areas nutrition, physical activity, and psychosocial factors.
1. A use of a compound of the formula    wherein X = C1-C4 alkylthio, and Y = C1-C4 alkyl or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof for the treatment of attention-deficit/huperactivity disorder of duloxetine. 2. A use of claim 1 wherein the predominantly inattentive type of attention-deficit/hyperactivity disorder is to be treated. 3. A use of claim 1 wherein the predominantly hyperactive-impulsive type of attention-deficit/hyperactivity disorder is to be treated. 4. A use of claim 1 wherein the combined type of attention-deficit/hyperactivity disorder is to be treated. 5. A use of claim 1 wherein the patient to be treated is a child. 6. A use of claim 1 wherein the patient to be treated is an adolescent. 7. A use of claim 1 wherein the patient to be treated is an adult. 8. A use of a compound of the formula   wherein X = C1-C4 alkylthio, and Y = C1-C4 alkyl or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of attention-deficit/hyperactivity disorder of duloxetine. 9. A use of claim 8 wherein the predominantly inattentive type of attention-deficit/hyperactivity disorder is to be treated. 10. A use of claim 8 wherein the predominantly hyperactive-impulsive type of attention-deficit/hyperactivity disorder is to be treated. 11. A use of claim 8 wherein the combined type of attention-deficit/hyperactivity disorder is to be treated. 12. A use of claim 8 wherein the patient to be treated is a child. 13. A use of claim 8 wherein the patient to be treated is an adolescent. 14. A use of claim 8 wherein the patient to be treated is an adult. 15. A use of a pharmaceutical composition comprising a pharmaceutical carrier and a compound of the formula I   wherein X = C1-C4 alkylthio, and Y = C1-C4 alkyl or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof for the treatment of attention-deficit/hyperactivity disorder. 16. A composition of claim 15 wherein the predominantly inattentive type of attention-deficit/hyperactivity disorder is to be treated. 17. A composition of claim 15 wherein the predominantly hyperactive-impulsive type of attention-deficit/hyperactivity disorder is to be treated. 18. A composition of claim 15 wherein the combined type of attention-deficit/hyperactivity disorder is to be treated. 19. A composition of claim 15 wherein the patient to be treated is a child. 20. A composition of claim 15 wherein the patient to be treated is an adolescent. 21. A composition of claim 15 wherein the patient to be treated is an adult. 22. A use of any one of claims 1-14 wherein the compound is N-methyl-3-(2-methylthiophenoxy)-3-phenylpropylamine or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof. 23. A use of any one of claims 15-21 wherein the compound is N-methyl-3-(2-methylthiophenoxy)-3-phenylpropylamine or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof.
<P>PROBLEM TO BE SOLVED: To provide a novel disaccharide containing a rare saccharide as a constituent monosaccharide; and its synthetic method.  <P>SOLUTION: The novel disaccharide containing a rare saccharide as a constituent monosaccharide is α-D-glucopyranosyl-(1→2)-β-D-psicofuranoside with a molecular weight of 342.30. The novel disaccharide is synthesized by using sucrose as a starting material and by the coupled reaction of sucrose phosphorylase with D-tagatose 3-epimerase in the presence of an inorganic phosphoric acid. Another synthetic method is also provided, by which the novel disaccharide is synthesized by causing sucrose phosphorylase to act on α-glucose-1-phosphoric acid and a ketohexose selected from rare saccharides. The ketohexose selected from rare saccharides is at least one ketohexose selected from the group consisting of D-psicose, D-tagatose, D-sorbose, L-fructose, L-psicose, L-tagatose, and L-sorbose.  <P>COPYRIGHT: (C)2007,JPO&INPIT
Two vaccinations with H9N2 (6-2) AA ca Reassortant (A/chicken/Hong Kong/G9/97 x A/Ann Arbor/6/60 ca) vaccine at a dose of 10\^7 TCID50 delivered by nose drops. The second vaccination will be given 4 to 12 weeks after the first.
The current studies have shown that the occurrence and development of chronic obstructive pulmonary disease (COPD) are closely related to the changes in gut health and its microenvironment, and even some gut diseases have significant clinical correlation with COPD. The dysbiosis of gut microbiota observed in COPD patients also suggests a potential bidirectional interaction between the gut and lung. Communication between the gut and lung may occur through circulating inflammatory cells, gut microbial metabolites, and circulating inflammatory mediators, but the mechanism of bidirectional communication between the gut and lung in COPD is still under study. Therefore, more research is still needed in this area. In this review, we summarize recent clinical studies and animal models on the role of the gut-lung axis in the occurrence and development of COPD and its mechanisms, so as to provide ideas for further research in this field. In addition, we also summarized the negative effects of COPD medication on gut microbiota and the gut microbiota risk factors for COPD and proposed the potential prevention and treatment strategies.
Participants will receive 2 acupuncture treatments each week for 5 weeks, for a total of 10 treatments. Each acupuncture treatment will take 30 minutes.
People always use the sodium hydroxide and the vegetable oil add a little surfactant as cleansing cosmetics, but it cannot be used on the face and delicate skin. Although amino acid soaps can be used on the face and delicate skin have moisturizing after washing, but the foaming and cleaning ability is inferior to the general cleansing cosmetics. The inventor combined the essential flower peptide system (containing Essential Rose Oil, Flower Water, Copper Tripeptide, Honey and natural moisturizing factors) with amino acid soap, improves the cleaning effect and the foaming ability. The reason is an emulsification reaction during the friction process by the essential flower oil in the essential flower peptide system. The bubbles are dense like the fresh cream, have nice cleaning effect. The effective ingredients can deeply into the skin by carrier also achieves maintenance while cleaning.
This will be a prospective, randomized, controlled trial. The catheter is already in use at our facilities. After informed consent, patients will be randomly given the standard or new catheter in our practice. Envelopes with the random assignment will be available to the individuals consenting patients. Randomization generally ensures that study groups are similar on average. As age, sex, and weight impact image quality, we will collect data on these factors in case randomization results in an imbalance. This will allow for control of these factors in analysis of the data. Data will be collected from CT abdomen pelvis examinations within a 6 month-1 year period in 2016 - 2017. Our primary outcome is image quality, measured as tissue density and distribution of contrast within the liver, spleen, aorta and IVC. Our secondary outcomes include Peak Contrast Infusion Pressure and Injection Flow Rate. Possible adverse events for use of any type of catheter include contrast infiltration into the subcutaneous tissues which is a minor limited event. All infiltrations will be recorded as part of the permanent medical record, documented in the chart, and the referring physician notified. The patient will be assessed by a physician immediately and referred to the ED if necessary for further evaluation. Current technology utilizes Power injector equipment which alerts the technologist to the pressure being achieved. If the injection pressure exceeds 325 psi the Power injector automatically shuts off.
According to the World Health Organization-led Delphi consensus, long COVID corresponds to the occurrence of symptoms beyond twelve weeks after the onset of acute COVID-19 illness that cannot be explained by alternate diagnosis. This cross-sectional study aimed to analyse the impacts of long COVID on general health and psychosocial well-being. For this study, the participants were interviewed either face to face or via telephone, and their responses were recorded on a questionnaire capturing information on demographics, COVID-19 status, duration of symptoms and long COVID symptoms. The psychosocial impacts of the pandemic were assessed using scales like Short Mood and feeling questionnaire (sMFQ), Warwick-Edinburgh Mental Well-being Scale (WEMWBS), Generalized Anxiety Disorder Assessment (GAD-7) and Perceived Stress Scale (PSS). Regression analysis was conducted to analyse the predictors of long COVID. A total of 300 participants were interviewed, of which 155 (52%) had COVID-19 illness. Of these 54 (35%) had persistent symptoms for a period of more than 12 weeks classified as long COVID. Muscle problems and fatigue were the most frequent (14.7%) symptoms encountered, followed by breathing problems (12.6%) and cognitive issues (12.6%). The symptoms of decrease in appetite and confusion or disorientation during the initial phase of the infection were associated with long COVID. The majority of the participants (83.3%) had moderate level of perceived stress, while moderate to severe levels of stress were observed in 17.3% of the individuals. Moreover, a high level of positive mental well-being was also observed. This study highlights the need for further research into the clinical aspects and implications of long COVID in Pakistan and emphasizes the importance of ongoing support for affected individuals.
The present description relates to T-cell receptors (TCRs) binding to tumor-associated antigens (TAAs) for targeting cancer cells, T-cells expressing same, methods for producing same, and methods for treating cancers using same. In particular, the present description relates to TCRs and their variants that bind to HLA class I or II molecules with a peptide, such as IGF2BP3-001 have the amino acid sequence of KIQEILTQV (SEQ ID NO:1). The present description further relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present description relates to the immunotherapy of cancer. The present description furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T-cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
BACKGROUND: Clinicians regularly prescribe opioids to manage acute and chronic cancer pain, frequently to address acute postoperative pain, and occasionally to manage chronic non-cancer pain. Clinical efficacy may be suboptimal in some patients due to side effects and/or poor response, and opioid rotation/switching (conversions) is frequently necessary. Despite the widespread practice, opioid conversion ratios are inconsistent between clinicians, practices, and countries. Therefore, we performed a scoping systematic review of opioid conversion studies to inform an international eDelphi guideline.
METHODS: To ensure a comprehensive review, we conducted a systematic search across multiple databases (OVID Medline, PsycINFO, Embase, EBM-Cochrane Database of Systematic Reviews and Registered Trials, LILACS, IMEMR, AIM, WPRIM) using studies published up to June 2022. Additionally, we performed hand and Google Scholar searches to verify the completeness of our findings. Our inclusion criteria encompassed randomized and non-randomized studies with no age limit, with only a few pediatric studies identified. We included studies on cancer, non-cancer, acute, and chronic pain. The level and grade of evidence were determined based on the Multinational Supportive Care in Cancer (MASCC) criteria.
RESULTS: Our search yielded 21,118 abstracts, including 140 randomized (RCT) and 68 non-randomized (NRCT) clinical trials. We compared these results with recently published conversion ratios. Modest correlations were noted between published reviews and the present scoping systematic review.
CONCLUSION: The present scoping systematic review found low-quality evidence to support an opioid conversion guideline. We will use these data, including conversion ratios and type and route of administration, to inform an eDelphi guideline.
There is a growing interest in wearable inertial sensors to monitor and analyze the movements of pregnant women. The noninvasive and discrete nature of these sensors, integrated into devices accumulating large datasets, offers a unique opportunity to study the dynamic changes in movement patterns during the rapid physical transformations induced by pregnancy. However, the final cut of the third trimester of pregnancy, particularly the first stage of labor up to delivery, remains underexplored. The growing popularity of "walking epidural", a neuraxial analgesia method allowing motor function preservation, ambulation, and free movement throughout labor and during delivery, opens new opportunities to study the biomechanics of labor using inertial sensors. Critical research gaps exist in parturient fall prediction and detection during walking epidural and understanding pain dynamics during labor, particularly in the presence of pelvic girdle pain. The analysis of fetal descent, upright positions, and their relationship with dynamic pelvic movements facilitated by walking during labor is another area where inertial sensors can play an interesting role. Moreover, as contemporary obstetrics advocate for less restricted or non-restricted movements during labor, the role of inertial sensors in objectively measuring the quantity and quality of women's movements becomes increasingly important. This includes studying the impact of epidural analgesia on maternal mobility, walking patterns, and associated obstetrical outcomes. In this paper, the potential use of wearable inertial sensors for gait analysis in the first stage of labor is discussed.
BACKGROUND AND PURPOSE: In patients with epilepsy and sustained seizure freedom, guidelines recommend considering discontinuation of antiseizure medication (ASM) based on shared decision-making. This study aims to identify factors associated with non-discontinuation of ASM in seizure-free patients.
METHODS: Retrospective data from three sites of an academic outpatient clinic were analyzed. Adult patients with epilepsy who have been seizure-free for ≥24 months on ASM monotherapy were included. The primary end-point was non-discontinuation of ASM, defined as no discontinuation or no dose reduction of ≥25% at the last outpatient clinic visit in the ultimate seizure-free interval. Secondary end-points included frequency of discussion on discontinuation attempts between patients and physicians, adherence to ASM discontinuation decisions, and post-discontinuation seizure outcomes.
RESULTS: Out of 338 included patients, 81.7% did not discontinue ASM and did not reduce its dose, 11.5% discontinued ASM and 6.8% had a significant dose reduction. Factors independently associated with non-discontinuation of ASM were history of focal to bilateral or generalized tonic-clonic seizures (odds ratio [OR] 2.33, 95% confidence interval [CI] 1.08-5.06), history of breakthrough seizures (OR 3.32, 95% CI 1.10-10.04), history of failed attempts to discontinue or reduce the ASM dose (OR 4.67, 95% CI 1.03-21.11) and higher ASM load at the index visit (OR 6.10, 95% CI 2.09-17.78). Discontinuation attempts were made during the entire period of seizure freedom and were most commonly undertaken ≥10 years after the last seizure.
CONCLUSIONS: This study provides insights into factors associated with the shared decision-making process regarding ASM discontinuation in seizure-free patients and highlights the importance of considering individual patient characteristics and seizure history.
INTRODUCTION: Therapeutic antibodies have become a major strategy to treat oncologic diseases. For chronic lymphocytic leukemia, antibodies against CD20 are used to target and elicit cytotoxic responses against malignant B cells. However, efficacy is often compromised due to a suppressive microenvironment that interferes with cellular immune responses. To overcome this suppression, agonists of pattern recognition receptors have been studied which promote direct cytotoxicity or elicit anti-tumoral immune responses. NOD2 is an intracellular pattern recognition receptor that participates in the detection of peptidoglycan, a key component of bacterial cell walls. This detection then mediates the activation of multiple signaling pathways in myeloid cells. Although several NOD2 agonists are being used worldwide, the potential benefit of these agents in the context of antibody therapy has not been explored.
METHODS: Primary cells from healthy-donor volunteers (PBMCs, monocytes) or CLL patients (monocytes) were treated with versus without the NOD2 agonist L18-MDP, then antibody-mediated responses were assessed. In vivo, the Eµ-TCL1 mouse model of CLL was used to test the effects of L18-MDP treatment alone and in combination with anti-CD20 antibody.
RESULTS: Treatment of peripheral blood mononuclear cells with L18-MDP led to activation of monocytes from both healthy donors and CLL patients. In addition, there was an upregulation of activating FcγR in monocytes and a subsequent increase in antibody-mediated phagocytosis. This effect required the NF-κB and p38 signaling pathways. Treatment with L18-MDP plus anti-CD20 antibody in the Eµ-TCL model of CLL led to a significant reduction of CLL load, as well as to phenotypic changes in splenic monocytes and macrophages.
CONCLUSIONS: Taken together, these results suggest that NOD2 agonists help overturn the suppression of myeloid cells, and may improve the efficacy of antibody therapy for CLL.